VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Size is predicted to expand with a 6.8% CAGR during the forecast period for 2025-2034.
Inhibitors of VEGF (Vascular Endothelial Growth Factor) are a standard treatment for diabetic retinopathy, particularly in cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). These medications function by targeting VEGF, a protein that promotes the formation of abnormal blood vessels and increases vascular permeability in the retina, two key mechanisms underlying the progression of diabetic retinopathy. Elevated VEGF levels in the diabetic retina led to neovascularization, increased vascular leakage, causing macular edema, and progressive retinal damage, which can result in vision loss. By blocking VEGF activity, these inhibitors prevent the growth of abnormal blood vessels, reduce fluid leakage and retinal swelling, and ultimately help to stabilize or even improve visual acuity in affected patients.
Ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, is a key treatment for diabetic retinopathy, including diabetic macular edema (DME). It works by inhibiting the formation of abnormal new blood vessels and reducing fluid leakage in the retina, two hallmark features of diabetic retinopathy. Ranibizumab is a recombinant humanized monoclonal antibody fragment that selectively binds to VEGF-A, a protein that promotes angiogenesis, thereby effectively suppressing disease progression. Alongside ranibizumab, other VEGF inhibitors such as aflibercept, bevacizumab, and faricimab have demonstrated strong clinical efficacy in reducing macular edema and improving or stabilizing vision. Growing emphasis on early detection and treatment, supported by advancements in non-invasive imaging and teleophthalmology, further supports the expanding role of anti-VEGF therapies in the management of diabetic retinopathy.
Competitive Landscape
Some of the Major Key Players in the VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market are:
- Regeneron Pharmaceuticals, Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Genentech, Inc. (Roche subsidiary)
- Kodiak Sciences Inc.
- Innovent Biologics, Inc.
- Ashvattha Therapeutics, Inc.
- UNITY Biotechnology, Inc.
- PanOptica, Inc.
- Regenxbio Inc.
- Ocular Therapeutix, Inc.
- Adverum Biotechnologies, Inc
Market Segmentation
The VEGF inhibitors therapeutic for the diabetic retinopathy market is segmented based on drug type, indication, and delivery method. Based on Drug Type, the market is segmented into aflibercept, ranibizumab, bevacizumab, faricimab, biosimilars, and pipeline drugs. Based on the Indication, the market is divided into diabetic macular edema (DME), proliferative. diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR). Based on the delivery method, the market is divided into intravitreal injections, sustained-release implants, and emerging technologies.
The Aflibercept (Eylea) Segment is Expected to Have the Highest Growth Rate During the Forecast Period.
Based on Drug Type, the market is segmented into aflibercept, ranibizumab, bevacizumab, faricimab, biosimilars, and pipeline drugs. the aflibercept (Eylea) segment is expected to have the highest growth rate during the forecast period. Eylea has demonstrated strong clinical efficacy in stabilizing and improving vision in patients with retinal diseases. It is approved for multiple indications, including wet age-related macular degeneration (AMD), DME, and diabetic retinopathy, making it a versatile treatment option. The introduction of Eylea HD, an 8 mg high-dose formulation, allows for longer intervals between injections (up to 16 weeks), reducing the treatment burden on patients and healthcare providers.
The Non-Proliferative Diabetic Retinopathy (NPDR) Segment Dominates the Market
Based on the Indication, the market is divided into diabetic macular edema (DME), proliferative. diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR). Among these, the non-proliferative diabetic retinopathy (NPDR) segment dominates the market. There's a growing emphasis on early detection and treatment of diabetic retinopathy. Initiating anti-VEGF therapy during the NPDR stage can prevent progression to more severe forms, such as Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME). Studies have demonstrated that early treatment of severe NPDR with anti-VEGF agents leads to a significant reduction in the risk of progression to PDR.
North America Has the Largest Market Share During the Forecast Period.
The North America region particularly the United States, holds the largest share of the VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market during the forecast period. North America boasts a well-developed healthcare system with widespread access to eye care specialists and advanced diagnostic technologies, which facilitates the early detection and effective treatment of diabetic retinopathy.
The United States, in particular, has a significant diabetic population, contributing to a higher incidence of diabetic retinopathy and a corresponding increase in demand for targeted therapies. Additionally, the region has demonstrated rapid adoption of innovative treatments, including anti-VEGF agents, driven by robust clinical research infrastructure and timely regulatory approvals. These factors collectively support North America's leading position in the VEGF inhibitors therapeutic market for diabetic retinopathy.
Recent Developments:
- In March 2025, Kodiak Sciences Inc. declared that it has finished enrolling patients with diabetic retinopathy ("DR") in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer. " With the added benefit of an extra loading dosage to give physicians more dosing options, the GLOW2 design is similar to the successful GLOW1 research. They expect to have a regulatory package for tarcocimab that is prepared for filing if the results of GLOW2, the second registrational study in diabetic retinopathy, are favorable.
- In July 2024, Genentech, a member of the Roche Group, revealed two-year results from the Phase III Pagoda and Pavilion trials, which assessed Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME), the two main conditions that cause vision loss in diabetic people. The first and only refillable eye implant that uses the Port Delivery Platform to continuously supply a tailored ranibizumab formulation is Susvimo.
VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 6.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, Indication, Delivery Method |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Regeneron Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Genentech, Inc. (Roche subsidiary), Kodiak Sciences Inc, Innovent Biologics, Inc, Ashvattha Therapeutics, Inc, UNITY Biotechnology, Inc, PanOptica, Inc, Regenxbio Inc. Ocular Therapeutix, Inc, Adverum Biotechnologies, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
